Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz

Tempus AI says ALERT trial shows higher valve procedures and faster care, while analysts keep a Buy rating with varied price targets.

Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

Infinimmune, Merck ink deal to develop human-derived antibodies using the Anthrobody platform. See the full agreement details.

FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Un

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda

Infinimmune Partners With Merck To Discover And Develop Therapeutic Antibodies Using Human-First AI Platform; Merck Will Have The Exclusive Right To Develop And Commercialize Antibody Candida

Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by MerckInfinimmune's platform combines large-scale human immune repertoire single cell screening with AI-guided

RBC Capital Reiterates Outperform on Merck & Co, Maintains $142 Price Target

RBC Capital analyst Trung Huynh reiterates Merck & Co (NYSE:MRK) with a Outperform and maintains $142 price target.

Merck Announced Results From Third Positive Phase 3 Comparative Study On Enlicitide Decanoate When Added To Background Statins In Adults With Hypercholesterolemia Who Have A History Of Or Are

Reported Sunday, Merck's Winrevair Demonstrates Statistically Significant 1.02 Wood Units Reduction In PVR In Phase 2 CADENCE Trial, Paving Way For Phase 3 Study

Merck's WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heartTotality of evidence across hemodynamic,